This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly (LLY) Stock Up on Raised 2021 View, Upbeat 2022 Guidance
by Zacks Equity Research
Eli Lilly's (LLY) stock rallies after it raises 2021 profit and sales outlook and provides an upbeat financial guidance for the next year.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $232.43, moving -0.98% from the previous trading session.
Ionis (IONS) Collaborates With AstraZeneca for Eplontersen
by Zacks Equity Research
Ionis (IONS) and AstraZeneca (AZN) are set to have joint development and commercialization rights of eplontersen in the United States. AstraZeneca will have exclusive rights to commercialize it in the rest of the world.
Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug
by Zacks Equity Research
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranolone.
Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More
by Zacks Equity Research
Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.
Why Is Biogen Inc. (BIIB) Down 5% Since Last Earnings Report?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote
by Zacks Equity Research
Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.
Cassava (SAVA) Down on Report of SEC Investigation Into AD Program
by Zacks Equity Research
Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.
Biotech Stock Roundup: REGN Gets EC Nod for Cocktail, BIIB's Drug Approval & More
by Zacks Equity Research
Drug approvals for Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Biogen's (BIIB) Oral MS Drug Vumerity Gets Approval in Europe
by Zacks Equity Research
Biogen's (BIIB) Vumerity gets marketing authorization in Europe for the treatment of adults with relapsing-remitting multiple sclerosis.
Biogen (BIIB) Up on New Data From Phase III Studies on Aduhelm
by Zacks Equity Research
Biogen's (BIIB) Aduhelm significantly lowers plasma p-tau-181, a pathological hallmark of Alzheimer's disease, in phase III studies.
Denali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement.
How Are Biotech ETFs Reacting to These Q3 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Ionis (IONS) Q3 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Ionis (IONS) incurs wider-than-expected Q3 loss. The company maintains its top-and bottom-line guidance for 2021
The Zacks Analyst Blog Highlights: Salesforce, AT&T, Boeing, Biogen and Arthur J. Gallagher & Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Salesforce, AT&T, Boeing, Biogen and Arthur J. Gallagher & Co
Top Research Reports for salesforce, AT&T & Boeing
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including salesforce.com, inc. (CRM), AT&T Inc. (T), and The Boeing Company (BA).
Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022
by Zacks Equity Research
Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.
Biogen (BIIB) Q3 Earnings Top, Aduhelm Sales Negligible
by Zacks Equity Research
Biogen (BIIB) beats third-quarter estimates for both earnings and sales and ups its financial guidance for 2021.
Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 14.94% and 3.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports third-quarter earnings.
Biogen's (BIIB) Tofersen Reports Mixed Data From ALS Study
by Zacks Equity Research
Biogen's (BIIB) phase III study evaluating tofersen for ALS with SOD1 mutation fails to meet the primary endpoint of the study. However, the study shows signs of reduced disease progression with tofersen.
Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline
by Zacks Equity Research
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.